229 related articles for article (PubMed ID: 17460706)
1. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
[No Abstract] [Full Text] [Related]
2. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
4. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
[TBL] [Abstract][Full Text] [Related]
5. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
Kanellopoulou T; Alexopoulou A; Koskinas J
Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
[No Abstract] [Full Text] [Related]
6. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
7. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
8. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
9. Inferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease.
Linnemann B; Kraft C; Roskos M; Zgouras D; Lindhoff-Last E
Thromb Res; 2012 Jun; 129(6):720-4. PubMed ID: 21982959
[TBL] [Abstract][Full Text] [Related]
10. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; FoĆ R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
11. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.
Qi X; Hu F; Yang Z; Han G; Fan D
Aliment Pharmacol Ther; 2011 Feb; 33(4):495-6; author reply 496-7. PubMed ID: 21235599
[No Abstract] [Full Text] [Related]
12. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
Dong B; Zhang Y; Fu X; Wang G
Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
[No Abstract] [Full Text] [Related]
13. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
[TBL] [Abstract][Full Text] [Related]
14. Quantification of JAK2V617F mutation by next-generation sequencing technology.
Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
[No Abstract] [Full Text] [Related]
15. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
[TBL] [Abstract][Full Text] [Related]
16. JAK2 mutations across a spectrum of venous thrombosis cases.
Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
[TBL] [Abstract][Full Text] [Related]
17. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
Goodyer M; Langabeer SE; Haslam K; Murphy K
Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
[No Abstract] [Full Text] [Related]
18. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
19. JAK2V617F mutation in patients with splanchnic vein thrombosis.
Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
[TBL] [Abstract][Full Text] [Related]
20. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]